Selective cleavage of ncRNA and antiviral activity by RNase2/EDN in THP1-induced macrophages

Lu Lu1,2 · Jiarui Li1 · Ranlei Wei3 · Irene Guidi1 · Luca Cozzuto4 · Julia Ponomarenko4 · Guillem Prats-Ejarque1 · Ester Boix1

Received: 5 October 2021 / Revised: 21 February 2022 / Accepted: 3 March 2022 / Published online: 26 March 2022
© The Author(s) 2022

Abstract
RNase2 is the member of the RNaseA family most abundant in macrophages. Here, we knocked out RNase2 in THP-1 cells and analysed the response to Respiratory Syncytial Virus (RSV). RSV induced RNase2 expression, which significantly enhanced cell survival. Next, by cP-RNAseq sequencing, which amplifies the cyclic-phosphate endonuclease products, we analysed the ncRNA population. Among the ncRNAs accumulated in WT vs KO cells, we found mostly tRNA-derived fragments (tRFs) and second miRNAs. Differential sequence coverage identified tRFs from only few parental tRNAs, revealing a predominant cleavage at anticodon and ρ-loops at U/C (B1) and A (B2) sites. Selective tRNA cleavage was confirmed in vitro using the recombinant protein. Likewise, only few miRNAs were significantly more abundant in WT vs RNase2-KO cells. Complementarily, by screening of a tRF & tiRNA array, we identified an enriched population associated to RNase2 expression and RSV exposure. The results confirm the protein antiviral action and provide the first evidence of its cleavage selectivity on ncRNAs.

Graphical abstract

Keywords RNase · Virus · RSV · miRNA · tRNA · tRF

Lu Lu and Jiarui Li both authors contributed equally to this work.

Extended author information available on the last page of the article
**Introduction**

Human RNase2 is a secretory protein expressed in leukocytes with a reported antiviral activity against single stranded RNA viruses [1, 2]. RNase2 is one of the main components of the eosinophil secondary granule matrix. The protein, upon its discovery, was named the Eosinophil Derived Neurotoxin (EDN), due to its ability to induce the Gordon phenomenon when injected into Guinea pigs [3–8]. Apart from eosinophils, RNase2 is also expressed in other leukocyte cell types, such as neutrophils and monocytes, together with epithelial cells, liver and spleen [8–10](https://www.proteinatlas.org/). The protein belongs to the ribonuclease A superfamily, a family of secretory RNases that participate in the host response and combine a direct action against a wide range of pathogens with diverse immunomodulation properties [2, 11].

RNase2 stands out for its high catalytic activity against single stranded RNA and its efficiency against several viral types, such as rhinoviruses, adenoviruses and retroviruses, including HIV [12–14]. Recently, presence of eosinophils and their associated RNases has been correlated to the prognosis of COVID patients [15–17]. On the contrary, no action is reported against the tested bacterial species [12, 18, 19]. In particular, among respiratory viruses, which activate eosinophil recruitment and degranulation, the human Respiratory Syncytial Virus (RSV), is the principal cause of death in infants [20], is probably the most studied model for RNase2 antiviral action. Indeed, RNase2 levels have predictive value for the development of recurrent wheezing post-RSV bronchiolitis [21]. RNase2 was proposed to have a role in the host response against the single stranded RNA virus [22] and early studies observed that RNase2 can directly target the RSV virion [12]. Interestingly, the protein ribonucleolytic activity is required to remove the RSV genome, but some structural specificity for RNase2 is mandatory, as other family homologues endowed with a higher catalytic activity are devoid of antiviral activity [23].

In our previous work we observed that RNase2 is the most abundantly expressed RNaseA superfamily member in the monocytic THP-1 cell line [24]. To broaden the knowledge of the immunomodulatory role and potential targeting of cellular RNA population by RNase2 in human macrophages, we built an RNase2-knockout THP-1 monocyte cell line using CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats) gene editing tool. Transcriptome of the RNase2 knockout with the unedited THP1-derived macrophage cells revealed that the top differently expressed pathways are associated to antiviral host defence (Lu et al., in preparation). Here, we explored the protein antiviral action by characterization of both THP-1 native and RNase2-KO cell lines exposed to RSV. The comparative study indicated that the knockout of RNase2 in THP1-derived macrophages resulted in a heavier RSV titre and reduced cell survival. Next, we analysed the total non-coding RNA (ncRNA) population by amplification of 2′3′-cyclic phosphate ends using the cP-RNAseq methodology and by screening a library array of tRNA-derived fragments. Results proved that RNase2 expression in macrophage correlates to a selective ncRNA cleavage pattern.

**Results**

**RSV activated the expression of RNase2 in macrophages**

RSV virus stock was obtained at a titration of $2.8 \times 10^6$ TCID$_{50}$/mL, as previously described [25] and THP-1 macrophages were exposed to the RSV at a selected MOI of 1:1 up to 72 h post of inoculation (poi). Following, we examined whether RSV addition induced the RNase2 expression in THP1-derived macrophages. The GAPDH gene was used as a housekeeping gene control. Figure 1A shows that unstimulated macrophage cells had a constant and stable transcriptional expression of RNase2 and it was significantly upregulated in a time-dependent manner upon RSV exposure. The significant RNase2 gene levels upregulation could be detected as early as at 4 h poi, with a sevenfold increase at 72 h poi. Furthermore, to determine whether the induction of RNase2 mRNA levels correlated with an increase in protein expression, ELISA and WB were conducted to detect intracellular and secreted RNase2 protein of THP1-derived macrophages. At indicated poi time, culture medium and whole-cell extracts of macrophages exposed to RSV were collected for ELISA and WB, respectively. As indicated in Fig. 1B, the secreted RNase2 protein was detected in human macrophages stimulated with RSV and was enhanced in response to RSV in a time-dependent manner, while no significant change of secreted RNase2 was detected in control macrophages. However, the maximum concentration of secreted RNase2 protein in macrophage culture was detected at 48 h poi, with a slight decrease at 72 h poi. Likewise, a similar profile was obtained by WB (Fig. 1C). Taken together, our results suggest that RSV induces both RNase2 protein expression and secretion in human THP1-induced macrophages.

**RNase2 protects macrophages against RSV**

To further characterize the protein mechanism of action, we knocked out RNase2 gene by the CRISPR/Cas9 methodology. RNase2 gene was successfully knocked out in 2 out of 32 single cells THP-1 derived cell lines, named as KO18 and
Both of KO18 and KO28 express a 15 residue-peptide in comparison to the wild type THP-1, which encodes the full-length protein of 134 residues (Fig. 2A). After confirmation of successful gene deletion by Sanger sequencing, we ensured that the expression of functional RNase2 has effectively been abolished. According to western blot (WB) assay, we can barely detect RNase2 in the KO18 cell lysate sample compared to the control sample and a total absence of signal is achieved in KO28 sample (Fig. 2B). Moreover, the total absence of secreted RNase2 by THP-1 cells was confirmed by ELISA assay in culture supernatant for KO28 line (Fig. 2C). Finally, we conducted the ribonuclease activity staining assay to evaluate the ribonucleolytic activity of the samples from cell lysates and culture supernatants. According to the activity staining electrophoresis, two main activity bands can be visualized in wild-type macrophage lysate sample, with molecular weight sizes around 15 and 20 kDa, corresponding to previously reported native forms [2, 7]. Compared to the WT control, both activity bands were missing in the RNase2 knockout cell lines (Fig. 2D). In addition, as recent studies suggested that CRISPR/Cas9 frequently induces unwanted off-target mutations, we evaluated the off-target effects on these transduced monocytes. Here, we examined the top four potential off-target sites for the sgRNA1 (Table S1) and did not detect off-target mutation in the T7EI assay (Fig. S1). Overall, we confirmed that the RNase2 gene has been both structurally and functionally knocked out. The KO28 THP-1 cell line, which achieved full RNase2-knockout, was selected for all the downstream experiments.

Next, we investigated whether RNase2 expression within macrophages contributes to the cell antiviral activity. First, THP-1 cells (WT and RNase2 KO) were induced into macrophages as described above. Macrophages were then exposed to RSV at MOI = 1 to investigate the kinetics of infection by monitoring both intracellular and extracellular RSV amplicon using probe RT-qPCR. Intracellularly, RSV levels increased during the first 24 h but decreased at longer periods (48–72 h), with a slow increase (0–4 h) followed by an exponential increase (4–24 h) and reaching a maximum at 24 h (Fig. S2A). At 24 h, RNase2 KO macrophages had significantly more intracellular RSV than WT macrophages. The extracellular RSV titre was also determined (Fig. S2B). We observed that RSV increased in KO macrophage cell cultures until 48 h and then stabilized at 48–72 h. While in WT macrophages, RSV profile showed an increase that reached a peak at 48 h and was followed by a decrease, significantly higher RSV levels were detected in KO macrophage cultures at 24–72 h. Moreover, we monitored cell death using MTT assay and our results confirmed that RSV exposure increased cell death in either WT or KO macrophages. However, significant differences were detected, where KO macrophage cell death upon RSV addition was higher than in WT macrophage cells (Fig. 3). Altogether, we concluded that RNase2 KO macrophages burdening and cell death following RSV exposure is significantly higher in comparison to WT macrophages. The present results confirm the direct involvement of the macrophage endogenous RNase2 in the cell antiviral activity.

Selective cleavage of RNase2 on ncRNA population

Following, we aimed to identify the potential changes in small RNA population associated to the expression of RNase2 by comparison of WT and KO cell lines. Toward
this end, we applied the cP-RNA-seq methodology that is able to exclusively amplify and sequence RNAs containing a 2′,3′-cyclic phosphate terminus, product of an enzymatic endonuclease activity [26]. Total small RNA from WT and KO-THP-1 cells was purified and the 20–100 nt fraction was extracted and processed as described in the methodology section. Sequence quality control indicated that for all samples more than 95% sequences achieved an average value > 30 M reads. Following RNAseq amplification, the sequence libraries were inspected by differential enrichment analysis. Principal Component Analysis (PCA) confirmed good clustering within WT and KO and appropriate discriminant power between the two groups (Fig. S3).

Results revealed that RNase2 expression in THP-1 cells is mostly associated to significant changes in small RNAs and in particular in tRNA fragments and miRNAs population (see Figs. S4–S6 and additional files 1–3). Overall, we observed an overabundance of only few specific tRNA-derived fragments (Fig. 4, Table S2 and Fig. S5) and miRNAs (Table S3 and Fig. S6).

Analysis of differential sequence coverage between WT and KO samples (Table S2) indicated that the preferential cleavage sites for RNase2 on tRNAs were CA and UA (Fig. 4). Figure 5A illustrates the base preferences for B1 and B2 deduced from the differential sequence coverage analysis of bam files. Results highlighted a selectivity for pyrimidines at B1 and preference for purines at B2, with a U/C ≥ 1 at the 5′ side of the cleavage site, and a pronounced predilection for A at the 3′ side. We also explored whether the cleavage preference was dependent on the RNA adopted secondary. We can see how RNase2 preferentially cuts at tRNA loops, mostly at the anticodon loop and secondarily at the D-loop, as well as stem regions near the anticodon loop (Fig. 5B).

On the other hand, analysis of ncRNA products by cP-RNAsesseq revealed abundance of miRNA products. Interestingly, out of the more than 2000 miRNAs in human genome
Selective cleavage of ncRNA and antiviral activity by RNase2/EDN in THP1-induced macrophages

Fig. 4 Predicted cleavage sites of the most significantly abundant tRNA-derived fragments identified by cP-RNAseq. Parental tRNAs with significant coverage differences between WT and RNase2-KO macrophage cells are depicted and the identified tRFs are marked in red. The possible cleavage sites are based on the 3’-terminal positions of the five prime fragments (blue arrows) and the 5’ terminal positions of three prime fragments (green arrows) according to the different coverage. Only sequences with a log2fold > 0.5 and adjusted p value < 0.05 are included.
Fig. 5 Overall cleavage preference of RNase 2 on tRNAs in THP-1 macrophage cells of WT vs RNase2-KO identified by cP-RNA-seq. A Estimated base preference at 5′ and 3′ of cleavage site (B1 and B2, respectively) deduced from analysis of differential sequence coverage. B Percentage of predicted cleavage location is depicted from low (white) to high (blue) values.

there were only 14 miRNA products significantly altered, of which several derived from the same parental miRNA precursor (additional file 3). Inspection of miRNA overrepresented in WT vs RNase2-KO by comparison of sequence coverage indicated a marked cleavage preference at the end of stem regions with a less defined base preference (see Fig. 6 and Table S3). Overall, we can infer for RNase2 a slight preference for U and C at B1 site, followed by G, and no defined consensus for B2.

In parallel, we decided to explore the changes in tRNA-derived fragments population associated with RNase2 expression in THP-1 cells by screening a tRNA-derived fragment library. The nrStar™ Human tRF&tiRNA PCR array includes a total of 185 regulatory tRNA-derived fragments, of which 110 are taken from the tRF and tiRNA databases and 84 have been recently reported in the bibliography. Using the nrStar™ Human tRF&tiRNA library, we found that out of a total of 185 tRNA fragments, only 5 were significantly decreased in RNase2 KO macrophage in comparison to the WT control group in non-treated samples and 22 under RSV exposure: 6 tiRNAs, 4 tRFs, 9 tRF-5, 4 tRF-3, 1 tRF-1 (see Table 1). Overall, the most significant changes associated to RNase2 in both cell cultures (p < 0.01) are observed in release products from few parental tRNAs.

Upon inspection of sequence of the putative cleavage sites we observed most sites at or near any of the tRNA loops, with predominance of anticodon loop (~50%), followed by D-loop (Table S4). Moreover, we observed that the preferred target sequences in WT samples were significantly enriched with U at the 5′ position of cleavage site, although not enough data is available for a proper statistical analysis. On the other hand, when analysing all the conditions, in the presence or absence of RSV, we also observed overall a significant preference for U at B1 at loop sequences. Moreover, the most significant tRNA fragments associated to RNase2 presence showed a U/C cleavage target for B1 at the anticodon loop (Table S4). On the contrary, the main base at B1 was G when the cleavage site was located at a stem region. As for the base located at the 3′ side of the cleavage target, we did not observe a clear distinct preference, with only a slight tendency for U, followed by A.

Overall, most of the parental tRNAs precursors identified by the array screening matched the identified by the cP-RNAseq assay (>70%), although some differences were observed in the identity of the accumulated fragments and their relative fold change. To note, few of the top listed precursors by the library screening (LysCTT and MetCAT) were also present in the amplified sequences by the cP-RNAseq, but with a lower abundance (Additional file 2). On the contrary, few of the top listed fragments spotted by the later methodology were absent from the commercial library array.

Notwithstanding, we must bear in mind that the results obtained from the tRNA array screening are determined by the intrinsic library composition. The tiRNA & tRFs list is based on the previously reported tRNA fragments, which have been identified mainly by the characterization of other RNases [27]. On the contrary, by cP-RNAseq method only the RNA by-products of an endonuclease enzymatic cleavage are amplified.

In addition, we confirmed tRNA cleavage by RNase2 in vitro by assaying the recombinant protein activity on synthetic tRNAs. The most representative sequences identified by tiRNA&tRFs list (p < 0.01) screening and two additional sequences found using the cP-RNAseq method, were incubated with RNase2 and tRNA cleavage products were visualized by urea-PAGE electrophoresis (see Fig. S9). The results highlighted a selective cleavage by RNase2. Comparative analysis using RNase5 as a reference showed a similar but differentiated cleavage pattern for both RNases. Besides, we obtained a distinct distribution of tRFs products as a function of the parental tRNAs substrates.

The present study is the first characterization of the catalytic activity of RNase2 on cellular ncRNAs and represents the first evidence of a specific release of tRNA fragments associated to RNase2 expression.
Discussion

Expression of human RNase2 is widely distributed in diverse body tissues, such as liver and spleen, together with leukocyte cells [2]. Among the blood cell types, RNase2 is particularly abundant in monocytes [11], which are key contributors to host defence against pathogens. A number of host defence-associated activities have been proposed for RNase2, mostly associated to the targeting of single stranded RNA viruses [1]. In particular, the protein has been reported
to reduce the infectivity of the human respiratory syncytial virus (RSV) in cell cultures [2, 12, 23].

Here, we studied RNase2 expression in THP1-derived macrophages exposed to RSV. Previous work indicated that RNase2 is the most abundant RNaseA family member expressed in this human monocytic cell line [24, 28] (https://www.proteinatlas.org/). Viruses can manipulate cell biology to utilize macrophages as vessels for dissemination, long term persistence within tissues and virus replication [29]. Although the epithelial airway is the principal RSV target, macrophages mostly contribute to the overall host immune response [30–32]. In our working model, we observed how RSV enters human THP1-induced macrophages within the first 2 h of inoculation. A fast proliferation of RSV takes place after 4 h post of inoculation and titre of intracellular RSV viruses reaches the highest peak at 24 h. Non-treated human THP1-derived macrophages stably expressed basal levels of RNase2 and upon 4 h of RSV addition the protein transcription is significantly activated, showing a time-line correlation between RSV population and RNase2 expression. Besides, a significant increase of the secreted protein is detected by ELISA after 24 h of inoculation, reaching a peak at 48 h (Fig. 1). It was previously reported that human monocyte-derived macrophages challenged with a combination of LPS and TNF-α produced RNase2 in a time-dependent manner [33]. However, we did not find any significant change of transcriptional expression of RNase2 upon Mycobacteria aurum infection [24]. Discrepancy of expression induction is also found for RNase2 secretion by eosinophils upon distinct bacterial infections. For example, Clostridium difficile and Staphylococcus aureus infection caused release of RNase2, while Bifidobacteria, Hemophilus, and Prevotella species infection did not [2]. In agreement, our previous work on THP1-derived macrophages infected by mycobacteria also

| Condition | Transcript name* | p value | Fold change | Type | tRF&tRNA precursor |
|-----------|------------------|---------|-------------|------|---------------------|
| WT vs KO  | 3'tiR_088_LysCTT (n) | 0.0085  | 4.11        | 3-half | LysCTT (n)          |
| KO + RSV vs WT + RSV | 3'tiR_060_MetCAT (n) | 0.0091  | 3.62        | 3-half | MetCAT (n)          |
| KO + RSV vs WT + RSV | TRF62 | 0.0360  | 2.39        | itRF | MetCAT          |
| KO + RSV vs WT + RSV | TRF315 | 0.0186  | 3.29        | itRF | LysCTT          |
| KO + RSV vs WT + RSV | TRF353 | 0.0243  | 3.90        | itRF | GluTGT          |
| KO + RSV vs WT + RSV | TRF419 | 0.0214  | 2.16        | itRF | LysTAA          |
| KO + RSV vs WT + RSV | tiRNA-5030-LysCTT-2 | 0.0322  | 2.94        | 5-half | LysCTT     |
| KO + RSV vs WT + RSV | tiRNA-5031-HisGTG-1 | 0.0345  | 2.79        | 5-half | HisGTG     |
| KO + RSV vs WT + RSV | tiRNA-5031-GluCTC-1 | 0.0155  | 3.05        | 5-half | GluCTC     |
| KO + RSV vs WT + RSV | 1001  | 0.0475  | 2.92        | tRF-1 | SerTGA     |
| KO + RSV vs WT + RSV | 1013  | 0.0488  | 4.36        | tRF-1 | AlaGC     |
| KO + RSV vs WT + RSV | 1039  | 0.0105  | 2.39        | tRF-1 | ArgCCT     |
| KO + RSV vs WT + RSV | 3004B | 0.0017  | 5.38        | tRF-3 | GluTGT     |
| KO + RSV vs WT + RSV | 3006B | 0.0473  | 2.13        | tRF-3 | LysTGT     |
| KO + RSV vs WT + RSV | 3016/18/22B | 0.0116  | 2.20        | tRF-3 | LysCTT/ MetCAT |
| KO + RSV vs WT + RSV | 5024A | 0.0118  | 3.84        | tRF-5 | LysTAA     |
| KO + RSV vs WT + RSV | 5032A | 0.0346  | 2.42        | tRF-5 | AspGTC     |
| KO + RSV vs WT + RSV | TRF356/359 | 0.0398  | 3.63        | tRF-5 | ArgTCG (n) |
| KO + RSV vs WT + RSV | TRF366 | 0.0285  | 2.85        | tRF-5 | ThrTGT     |
| KO + RSV vs WT + RSV | TRF365 | 0.0253  | 7.96        | tRF-5 | ThrTGT     |
| KO + RSV vs WT + RSV | TRF396 | 0.0462  | 2.39        | tRF-5 | AlaAGC     |
| KO + RSV vs WT + RSV | TRF457 | 0.0420  | 4.43        | tRF-5 | SerAGA     |
| KO + RSV vs WT + RSV | TRF550/551 | 0.0398  | 4.84        | tRF-5 | GluTTC/ GluCTC |

P value < 0.05 and absolute value of the fold change > 2 was set as the significant threshold

*185 tRNA fragments from four groups (WT, wild-type macrophage; KO, RNase2-knockout macrophage; WT + RSV, WT macrophage exposed to RSV; KO + RSV, KO macrophage exposed to RSV) were detected by using nrStar Human tRF&tRNA PCR Array and compared between each other.
discarded any induction of RNase2 expression [24]. In contrast, using the same working model and experimental protocol, we observe here how RSV exposure significantly activate both the expression and protein secretion of RNase2 in THP1-derived macrophage cells (Fig. 1). The present study corroborates previous reports on RNase2 involvement in host response to viral infections [1, 2, 34]. In particular, our work highlights the protein role in macrophage cells challenged by RSV. More importantly, we observe how the knockout of RNase2 in macrophage derived cells results in enhanced cell death (Fig. 3).

Considering previous reports on the contribution of RNase2 enzymatic activity in the protein antiviral activity [12] and the evidence that RSV infection alters the cellular RNA population, including the specific release of regulatory tRFs [35–37], we decided here to analyse the contribution of macrophage endogenous RNase2 on cellular small RNAs. Increasing data demonstrates that small noncoding RNAs (ncRNAs) play important roles in regulating antiviral innate immune responses [38–40]. In particular, ncRNAs derived from tRNAs, such as tRNA halves (tiRNAs) and tRNA-derived fragments (tRFs), have been identified and proven as functional regulatory molecules [41]. RSV infection together with other cellular stress processes can regulate the population of tiRNAs and tRFs. For example, it has been demonstrated that RSV infection and hepatitis viral infection can induce the production of tRFs and tRNA-halves, and their release has been related to RNase5 activity [36, 42]. RNase5, also called Angiogenin (Ang) due to its angiogenic properties, is one of the most well-known ribonucleases that are responsible for endonucleolytic cleavage of tRNA [43–45]. Surprisingly, the release of a specific tRF, tRF5-GluCTC, which targets and suppresses the apolipoprotein E receptor 2 (APOER2), can also promote the RSV replication [36, 37]. In the present study, although the tRF5-GluCTC was not significantly altered by RSV addition alone, we observed a significant reduction in the RNase2 knockout cell line challenged with RSV (Table 1). Besides, tRNA-5034-ValCAC, the 5’half originated from ValCAC, is identified both in the present work (Table S4) and the previous mentioned study associated to RSV infection [36]. To note, we found that RSV induced the production of 4 tRFs in WT macrophages, in agreement to the previous study that indicated that RSV infection induced the release of tRFs in A549 epithelial cells [36], although most of the tRNA products differ, which may be attributed to the specific basal composition of each source cell line [46]. Moreover, tRFs production is also observed to be dependent on the specific viral infection type; for example, human metapneumovirus, in contrast to RSV, did not induce tRFs but significantly altered miRNA population [40, 47]. Interestingly, release of tRNA products is mostly associated to an antiviral defence mechanism [48]. For example, the tRF3 from tRNA LysCTT, which stands out among the identified tRFs by our library array screening (Table 1), is reported to block retroviruses replication, such as in HIV-1, by direct binding to the virus priming binding site [49–51]. Other regulatory tRNA fragments underrepresented by RNase2-KO (such as 5’ LysCTT and GluCTC halves) (Table 1) were previously reported to be released by RSV infection [36, 37].

The present experimental data constitute the first evidence on the specific cleavage by RNase2 of cellular ncRNA. Results obtained by both cP-RNAseq and tRFs array screening indicate that RNase2 expression in macrophages is associated to the significant enrichment of selective miRNAs and tRNA-derived fragments (Figs. 4 and 6; Tables S2 and S3). In addition, a higher frequency of cleavage takes place at tRNA single stranded regions, with predilection for the anticodon loop, followed by the D arm (Fig. 5).

Exhaustive analysis of differential sequence coverage in WT and RNase2-KO THP-1 cells suggests that RNase2 preferentially targets at UA and CA sequences at tRNA loops. Recently, Bartok and co-workers reported a RNase2 selectivity for U at B1 site in synthetic RNAs [28]. Interestingly, according to Hornung and co-workers, the release of U > p ends by RNase2 would participate in the activation of TLR8 at the endolysosomal compartment and will contribute to sense the presence of pathogen RNA [52]. To note, we find a good agreement between RNase2 substrate specificity identified in the present cell assay study on tRNAs and the previously reported for synthetic single stranded oligonucleotides [53, 54] (see Table 2). However, some differences are evidenced at the miRNAs cleavage and in particular at the B2 site specificity, which does not fully match the reported on synthetic substrates. This discrepancy is also evident for the other two RNaseA family members described to release specific tRFs [55–58], i.e., RNase5/Ang and Onconase, an

### Table 2 Comparison of RNase2 cleavage specificity on ncRNA in THP1-derived macrophages (this study) with synthetic RNA substrates in vitro

| Synthetic RNA | Base preference | Ref Cellular RNA | Base preference |
|---------------|----------------|-----------------|----------------|
| B1            |               |                 |                |
| polyU/polyC   | U/C ~ 2        | [98] tRNA (loops) | U/C ~ 1.2      |
| polyU/polyC   | U/C ~ 1        | [97] tRNA (stems) |                |
| ORNs#         | U/C ~ 1.3      | [28] miRNA      | U–U (loops)    |
|               |                |                 | G–G (stems)    |
| B2            |               |                 |                |
| UpA/UpG       | (A/G ~ 47)     | [97] tRNA (loops) | A               |
| UpA/UpG       | (A/G > 100)    | [59] miRNA      |                |
| ORNs#         | G ≥ A ≥ U ≥ C  | [28]            |                |

*ORNs (short single-stranded oligonucleotides: ssRNA40, 9.2 s RNA, and R2152)

*This study
RNase purified from *Rana pipiens* with antitumoral properties (Table S5). Previous kinetic studies on RNAse A family cleavage preference using single stranded RNA substrates revealed a specificity for pyrimidines at the main B1 site and preference for purines at B2 [53, 54]. Among the family members, we observe distinct preferences for U vs C and A vs G at B1 and B2 sites, respectively. Interestingly, RNase 2 shows a marked preference for U at B1 and A at B2 on synthetic oligonucleotides [53, 59], which mostly corresponds to the observed preference identified by cP-RNAsseq for tRNA in this study (Fig. 5). Nevertheless, our analysis on tRNA cleavage sites would suggest a U/C ratio for B1 a bit lower than the estimated for some synthetic substrates (Table 2).

The present study on cellular ncRNA also highlights the key role of the RNA 3D structuration. Overall, our data reveal a cleavage preference by RNase 2 at single stranded sequences and secondarily at stem adjacent to loop regions. Besides, we also observe that location of the targeted site also influences the cleavage base preference.

Interestingly, previous kinetic and structural studies on RNAse A highlighted the unusual enhancement of the protein affinity to a dinucleotide probe by addition of a phosphate linkage insert that can adopt a contorted conformation close to the cleavable 3′5′ phosphodiester bond [60–62]. Likewise, previous work on Onconase nucleotide base selectivity also encountered significant differences in vitro among di and tetranucleotides [63] and tRNA [57].

In addition, the cleavage of tRNAs by RNases would probably be modulated by the presence of regulatory proteins within the cell [64]. For example, tRNA can be protected by Schlafen 2 (SLFN2) protein from cleavage by RNase 5 during oxidative-stress response [65]. Onconase specificity for specific tRNAs was attributed to the presence in vivo of RNA binding proteins that might protect RNA regions from RNase activity [56, 66]. In this context, we should consider the formation of regulatory complexes, such as the RISC formation, the binding of Argonaute (AGO) subunits [67] or interactions with the RNHI. On its turn, the released tRNA products would regulate the formation of cellular complexes. For example, tRF3 interaction with AGO2 mediates the cleavage of complementary Priming Binding Sequences (PBS) in retroviruses and thereby can avoid the replication of endogenous virus elements [68]. Interestingly, a recent study demonstrates a direct interaction between AGO4 and the RSV-induced GluCTC-tRF5 fragment [69].

Among the ncRNA population mostly altered upon RNase 2 knockout, we find, together with tRFs, miRNAs. Interestingly, the identified miRNAs subproducts come frequently from the same group of parental pre-miRNAs. Inspection on information related to these miRNAs entities reveals a predominance of miRNAs associated to cancer and neurological disorders, although few are also related to virus replication. However, caution should be taken when extracting conclusions, as miRNA databases are strongly biased from a predominance of previous clinical studies. We must also bear in mind that our working model (THP-1) is a leukaemia cell line. Accumulation of miRNAs can be toxic to the cells, due to their potential interference with the translation of essential proteins. Raines and co-workers correlated miRNA release by Ang with potential toxicity to cells [45]. In any case, in our working model we do not observe any change on the viability of both WT and KO cell lines.

On the other hand, we should be aware not to over interpret our results that could be also somehow biased by the applied methodologies. The RNAsseq methodology might lead to underrepresentation of some fragments, due to their relative size, short half-life or presence of posttranscriptional modifications. Therefore, caution must be taken when conclusions are drawn from the analysis of tRNA cleavage product population. Another important source of variability comes from the presence of posttranscriptional modifications, which can influence both the RNase selectivity and the product amplification step [26, 70]. Unfortunately, the current ncRNA databases are still incomplete and lack full information on the precise post-transcriptional modifications that take place in vivo and might intervene in the RNases recognition target.

More importantly, the array screening technique is prone to be biased by the selection criteria used to build the tRNA&tRF array; a library composed on previously available experimental data, i.e., products by RNases, such as Dicer, Angiogenin, RNAseP or RNAseZ. This might explain some of the differences observed in the identified fragments when comparing the screening of the tRFs array and the amplified sequences by the cP-RNAsseq methodology, which only amplifies the products of an endonuclease cleavage.

On the other hand, we should also take into account the protein traffic and accessibility to the distinct subcellular compartments in the assayed experimental conditions. For example, in contrast to RNase 5, mostly located at the nucleus, RNase 2 is associated to the endolysosomal compartment [28, 52, 67]. In addition, cleavage of cellular mature tRNAs might occur during stress conditions, when leakage of the RNases to the cytosol is favoured. We should bear in mind that the cell cytosolic RNA is in normal conditions protected by the presence of the RNHI, which would lose its functional conformation under stress conditions due to oxidation of surface exposed Cys residues [71]. Accordingly, in the case of RNase 5/Ang, it has been described that the selective tRNA cleavage takes place in oxidative conditions [55, 72, 73]. This might also explain the much higher number of tRNA fragments obtained in the present study in the RSV treated vs non-treated cells (Tables 1 and S4). Notwithstanding, recent bibliography indicates that other proteins may intervene in the regulation of the RNase–RNHI
complex [67] and further studies are needed to fully interpret our results.

Interestingly, under certain cell conditions, such as nutrition deficiency or oxidative stress, RNase5/Ang is reported to stimulate the formation of cytoplasmic stress granules and produce tRNA-derived stress-induced RNAs (tiRNAs) [74–76]. The released tiRNAs functionally enhance damage repair and cellular survival through suppressing the formation of the translation initiation factor complex or associating with the translational silencer [44, 68]. Ivanov and co-workers recently characterized the structural determinants that guide release of tiRNA population during stress conditions [58, 77]. Accessibility of tRNAs will also depend on their potential entrapment in Tbox riboswitch or RNA granules, which are abundant in starvation situation and have an unequal propensity to protect tRNA from cleavage. Besides, proteomic analysis revealed the presence of RNHI within stress granules [78], an inhibitor protein that can complex to RNase5/Ang and other regulatory proteins to control cell translation [67].

Another important source of variability comes from the assayed cell type. Although it is widely accepted that the levels of parental tRNAs differ significantly upon cell conditions and tissues [27] and a very unequal tissue distribution is observed for the more than 500 tRNAs listed in our genome, little is still known of their relative expression rates. Last but not least, the specific expression pattern of RNases associated to each cell type and experimental condition will definitely contribute to shape the ncRNA population. We must also take into consideration that our results are based on a single monocytic cell line, which undoubtedly cannot fully reproduce the alveolar macrophages that infiltrate within the lung epithelial barrier during virus respiratory tract infections.

Despite the inherent limitations of this study, our results confirm that RNase2 can target ncRNA and release specific miRNAs and tRFs. Particular interest should be drawn to the new identified tRNA fragments associated to RNase2 and absent from the commercial library array, which represent potential new regulatory elements for future studies. A growing evidence emphasizes the key role of tRNA halves and tRFs in regulating cellular functions [48, 79–81]. Deciphering the contribution of the distinct RNases to shape the cell ncRNA population should be key to analyse the cell response to adapt to distinct stress conditions, such as viral infection.

**Conclusions**

This is the first report of RNase2 selective targeting of ncRNA. We have engineered a THP-1 cell line defective in RNase2. Comparison of native and knockout THP1-derived macrophages exposed to RSV confirms the RNase involvement in the cell host antiviral defence. By amplification of 2′3′cP end RNA products, we have identified the tRNA fragments and miRNAs associated to RNase2 cleavage. The analysis of RNA recognition regions reveals the RNA base composition at the 5′ and 3′ of cleavage site. To note, tRNA cleavage is mostly favoured at anticodon and P-loops at UA and CA sites. Further work is mandatory for an unambiguous pattern assignment towards the understanding of how RNase2 can shape the ncRNA population and its antiviral role.

**Materials and methods**

**Plasmid construction**

For long term consideration, we used the two-plasmid system to run the CRISPR gene editing experiments instead of using all-in-one CRISPR system. Thus, we constructed a pLenti-239S coding Cas9, GFP and Puromycin resistance gene for the knockout assay by replacing the sgRNA expression cassette of LentiCRISPRv2-2-GFP-puro (gifted by Manuel Kaulich) short annealed oligos; for activation assay, we cloned the eGFP into lenti-dCAS-VP64-Blast (Addgene61425, gifted by Manuel Kaulich), the new plasmid was named pLenti-239G. Finally, plenti-239R, a new lentiGuide plasmid coding sgRNA expression cassette and Cherry fluorescence gene was created by using the Cherry gene (gifted by Marcos Gil, UAB) to replace the Cas9 of LentiCRISPRv2-2-GFP-puro (gifted by Manuel Kaulich). The primers used for PCR are listed in Table S6.

**sgRNA design and clone into pLentiGuide (pLenti239R) vector**

N20NGG motifs in the RNase2 locus were scanned, and candidate sgRNAs that fit the rules for U6 Pol III transcription and the PAM recognition domain of *Streptococcus pyogenes* Cas9 were identified. From CRISPOR (http://crispor.tefor.net/) and CRISPR-ERA, the top 2 sgRNA were selected for knockout RNase2. Using the same procedure, potential OT sites were also predicted. The sequences are listed in Table S1. Oligonucleotides were annealed and cloned into BbsI-digested pLenti-239R. The resulting plasmids containing sgRNAs were further confirmed by Sanger sequencing.

**Cell culture**

HEK293T cell line was kindly provided by Raquel Pequerul (UAB). HEK293T cell line was maintained in DMEM (Corning Life Science) supplemented with 10% foetal bovine serum (FBS) (Gibco). The culture media was...
replaced every 2–3 days, and the cells were passaged using Trypsin–EDTA Solution (Gibco, 25200056).

Human THP-1 cells (NCTC #88081201) were maintained or passaged in 25 or 75 cm² tissue culture flasks (BD Biosciences) using RPMI-1640 (Lonza, BE12-702F) medium with 10% heat-inactivated FBS at 37 °C in humidified 5% CO₂ conditions. The culture media was replaced every 2–3 days.

**Generation of lentiviral vectors**

To make the cell reach 90% confluence for transfection, 7.5 × 10⁶ of HEK293T cells were seeded in T75 culture flask with 15 ml DMEM + 10% FBS complete medium 1 day before transfection. The lentiviral plasmids were transfected into HEK293T cells using calcium phosphate protocol [82]. Briefly, 36 µg transfer plasmid, 18 µg psPAX2 packaging plasmid (Addgene#35002, gifted by Marina Rodriguez) and 18 µg pMD2G envelope plasmid (Addgene#12259, gifted by Marina Rodriguez) were mixed. Next, 93.75 µL of 2 M CaCl₂ was added and the final volume was adjusted to 750 µL with H₂O. Then, 750 µL of 2× HBS buffer was added dropwise and vortexed to mix. After 15 min at room temperature, 1.5 mL of the mixture was added dropwise to HEK293T cells and the cells were incubated at 37 °C at 5% CO₂ for 6 h; then the medium was replaced with pre-warmed fresh medium. After 24 h, 48 h, and 72 h, the supernatant was collected and cleared by centrifugation at 4000×g for 5 min and passed through 0.45 µm filter. Then, the supernatant fraction was concentrated by PEG6000 precipitate method [83] and the concentrated virus stock was aliquoted and stored at −80 °C.

**Cell transduction**

5 × 10⁵ THP-1 monocytes were infected with 20 µL concentrated lentivirus in the presence of 8 µg/mL polybrene overnight. Next day, the cells were replaced with fresh medium and cultured for 72 h. Fluorescence positive monocytes were checked by fluorescence microscopy and then sorted by Cell sorter. After the transduction, cells were resuspended and fixed by 2% paraformaldehyde in PBS for 10 min prior to flow cytometer. Single cells were sorted by Cell sorter BD FACSJazz.

**Sanger sequencing**

Briefly, the genomic DNA of THP-1 cells was extracted using GenJET Genomic DNA purification kit (ThermoFisher, K0721) and was further used to amplify RNase2 using NZYTaq II 2× Green master mix (NZYTech, MB358). Genomic DNA was subjected to PCR (BioRad) using primers listed in Table S1. The general reaction conditions were 95 °C for 10 min followed by 30 cycles of 95 °C for 30 s, annealing at 60 °C for 30 s, and extension at 72 °C for 30 s. The pairs of primers were designed to amplify the region that covers the two possible double breaking sites. The PCR product is 410 bp. After each reaction, 200 ng of the PCR products were purified using a QIAquick PCR Purification Kit (QIAGEN), subjected to T7E I assays, and then analysed by agarose gel electrophoresis. The indel mutation was confirmed by Sanger Sequencing.

**Construction of RNase2-KO THP-1 cell line**

A lentiviral system was selected to deliver CRISPR components into the THP-1 monocytic cell line. Cas9 and sgRNAs lentiviral particles were produced in HEK293T cells by Calcium phosphate precipitation method as previously reported [82–84]. THP-1 cells were then transduced with the concentrated lentiviral particles with 10 µg/mL of polybrene, the overall transduction efficiency is about 7% (Fig. S7). We designed 2 single guide RNAs (sgRNAs) (Table S1) targeting the RNase2 locus to generate double strand breaks (DSBs) (Fig. S8A). T7EI assay was employed to select the more active guide RNA, achieving the knockout efficiencies of about 40% (Figs. S8B and S8C). The GFP and cherry red double fluorescence positive cells were then sorted by FACS into single cells and were further allowed to grow into a single cell derived clonal cell line. Following, the genomic DNA was extracted from the single cell derived cell lines and further used as a template to amplify RNase2 using the primers covering the potential mutation sites. After Sanger sequencing validation, cell lines, where RNase2 gene knockout was successful were identified.

**T7 endonuclease I assay-gene editing detection**

As illustrated above, 200 ng of the purified RNase2 PCR products were denatured and re-annealed in 1× T7EI Reaction Buffer and then were incubated with or without T7EI (Alt-R® Genome Editing Detection Kit, IDT). The reaction mixtures were then separated by 2% agarose gel electrophoresis. The knockout efficiency (KO%) was determined using the following formula: KO% = 100 × (1 − [1 − (a + b)]/2), where a is the integrated intensity of the undigested PCR product and b is the combined integrated intensity of the cleavage products [85].

**Protein detection by western blot and ELISA**

For the western blot assays, 5 × 10⁵ cells with or without transduction and their supernatants were harvested with RIPA buffer and the protein concentration was determined with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, 23225). Equal amounts of protein (50 µg) for each
sample were loaded and separated by 15% SDS–PAGE, transferred to polyvinylidene difluoride membranes. Then the membrane was blocked with 5% non-fat milk in TBST for 1 h at room temperature, and incubated with rabbit source anti-RNase2 primary antibody (Abcam, ab103428) overnight at 4 °C. After washing, the membranes were treated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (Sigma Aldrich, 12-348) for 1 h at room temperature (RT). Finally, the membranes were exposed to an enhanced chemiluminescent detection system (SuperSignal West Pico Chemiluminescent Substrate, ThermoFisher Scientific, 32209). As a control, GAPDH was detected with chicken anti-GAPDH antibodies (Abcam, ab9483) and goat anti-chicken secondary antibody (Abcam, ab6877).

Secretory RNase2 in cell culture was detected by using human RNASE2 ELISA Kit (MyBioSource, MBS773233). Beforehand, the supernatant of the culture was concentrated 50 times using 15 kDa cutoff centrifugal filter unit (Amicon, C771S). Following, the standard and the concentrated culture supernatants were loaded to wells pre-coated with anti-RNase2 antibody, then the HRP-conjugated reagent was added. After incubation and washing for the removal of unbound enzyme, the substrate was added to develop the colour reaction. The colour depth or light was positively correlated with the concentration of RNase2. Triplicates were performed for all assays.

**Zymogram/ Ribonuclease activity staining assay**

Zymograms were performed as previously described [86]. 15% polyacrylamide–SDS gels were casted with 0.3 mg/mL of poly(U) (Sigma Aldrich, P9528-25MG). Then, cells were collected by centrifugation and resuspended in 10⁶ cells/ml with 1% SDS buffer. After sonication, cell lysate with indicated number of cells was loaded using a loading buffer that does not contain 2-mercaptoethanol. Electrophoresis was run at a constant current of 100 V for 1.5 h. Following, the SDS was removed by washing with 10 mM Tris/HCl, pH 8, and 10% (v/v) isopropanol for 30 min. The gel was then incubated for 1 h in the activity buffer (100 mM Tris/HCl, pH 8) to allow ribonuclease digestion of the embedded substrate and then stained with 0.2% (w/v) toluidine blue in 10 mM Tris/HCl, pH 8, for 10 min. Positive bands appeared white against the blue background after distaining.

**RSV treatment of THP-1-induced macrophages**

Before RSV inoculation, THP-1 cells were induced to macrophage by 50 nM of PMA treatment for 48 h as previously described [24]. Cells were washed three time with pre-warmed PBS and replaced with fresh RPMI + 10%FBS medium for 24 h incubation. After that, macrophages were washed and incubated with RSV, mixing at every 15 min for the first 2 h. All virus treatment tests were performed using RSV at a MOI of 1 TCID_{50}/cell.

**Real-time quantitative PCR**

RSV quantification were detected by real-time quantitative PCR. After the indicated time post of inoculation, the extracellular RSV virus were collected by PEG6000 precipitation method and intracellular RSV virus were collected by lysing the macrophage cells with the lysis buffer from mirVanaTM miRNA Isolation Kit (Ambion, Life Technologies, AM1560). Total RNA from RSV treated macrophage cells as well as stock virus was extracted using mirVanaTM miRNA Isolation Kit according to the manufacturer’s instructions. cDNA was synthesized using iScriptTM cDNA Synthesis Kit (Bio-Rad, 170-8891). The synthesis was performed using random hexamers, starting with 1 µg of total cell RNA. The RT-qPCR was performed using ddPCR™ Supermix for Probes (Bio-Rad, 1863024). Samples with a cycle threshold value of more than 40 were recorded as negative. A standard curve was prepared using serially diluted RNA extracts from a known quantity and used to quantify RSV as TCID_{50}/mL. In parallel with the RSV probe assays, an endogenous glyceraldehyde-3-phosphate dehydrogenase (GAPDH) control was used for relative quantification of the intracellular virus. The relative expression of GAPDH and RNase2 gene in macrophages was quantified by real-time PCR using iTaq Universal SYBR Green Supermix (Bio-Rad, 1725120). The primers and probe [89] used are listed in Table S6.
Cell viability assay

THP-1 monocytes (wild type or RNase2 knockout) were seeded at 5 × 10^4 cells/well in 96 well plates and differentiated into macrophages as described [24]. After treatment with RSV under MOI = 1 for different times, dynamic cell viability was measured using MTT assay.

Selective amplification and sequencing of cyclic phosphate-containing RNA (cP-RNA-seq)

Selective amplification and sequencing of cyclic phosphate-containing RNAs was performed as previously reported [26]. Briefly, small RNAs (< 200 nt) were extracted using mirVana™ miRNA Isolation Kit (Ambion, Life Technologies, AM1560) as described by the manufacturer. Following RNA extraction, 20- to -100nt RNAs were purified from 8% TBE–PAGE gel. By the manufacturer. Following RNA extraction, 20- to -100nt RNAs were purified from 8% TBE–PAGE gel. Then, the purified RNAs were treated by calf intestinal alkaline phosphatase. After phenol–chloroform purification, directed ligation of adapters, cDNA generation, and PCR amplification were performed using the Truseq Small RNA Sample Prep Kit for Illumina (NewEngland Biolabs, E7335S) according to the manufacturer’s protocol. The amplified cDNAs were sequenced using Illumina hiSeq2500 system at the Centre for Genomic Regulation, CRG, Barcelona.

For small RNA-seq analysis, skewer (v0.22) was used to remove the 5’adaptor sequences and discard low-quality reads [90]. Reads have been size selected before being aligned to the reference genome (GRCh38) with short-Stack based on bowtie1 aligner [91, 92]. The mapped reads were counted with HTSeq-count [93] using the annotation from miRBase version 22.1 ([http://www.mirbase.org/][94]). For differential analysis, DESeq2 [95] was used on count matrices of tRNA-derived fragments and miRNAs. Quantification of differential abundance of small RNAs was estimated by tRAX (http://trna.ucsc.edu/tRAX/). The selective cleavage was identified by comparison of the differential coverage in WT and KO samples. Complementarily, small RNAs were mapped based on NCBI ([https://www.ncbi.nlm.nih.gov/][97]) and Gencode 38 ([https://www.gencodegenes.org/][98]). The Integrative Genomics Viewer (IGV) was used for visualizing the aligned bam file reads and check the nucleotide composition at the putative cleavage site, which was estimated from the analysis of the differential sequence coverage of WT and RNase2-KO samples.

Probe amplification and purification

Total RNA was extracted by using mirVana miRNA Isolation Kit (Ambion, AM1556). Next, 2 μg of purified total RNA was used to create cDNA libraries from small RNAs for qPCR detection using rtStar First-Strand cDNA Synthesis Kit (ArrayStar, AS-FS-003). This method sequentially ligates 3’-adaptor with its 5’-end to the 3’-end of the RNAs, and 5’-adaptor with its 3’-end to the 5’-end of the RNAs. After cDNA synthesis, 185 (tRNA-derived fragments) tRFs & tRNA halves) tRFs were profiled and quantified by qPCR method using rtStar Human tRF&tiRNA PCR Array (ArrayStar, AS-NR-002).

In vitro Transcription (IVT) and analysis of tRNA degradation products

The preparation of synthetic tRNAs was performed using in vitro transcription (IVT) assay based on the T7 RNA polymerase reaction [96]. According to the sequence of interest, we first designed and amplified the dsDNA templates for IVT considering the preference of T7 RNA polymerase by replacing the first three bases by GGG in the targeted sequences. The corresponding synthetic primers (Sigma, Aldrich) are listed in Table S7. After PCR amplification, the product was washed and concentrated by Gelpure kit (NZYtech, MB01101).

A total of 1 μg of dsDNA templates was used for a 50 μl IVT reaction by following the manufacturer’s instructions (NZYtech, MB08001). In short, after 2 h of IVT reaction, DNase treatment was performed at 37 °C for 1.5 h. Next, we added the same volume of acid–phenol: chloroform (Ambion™, AM9722) to the mixture and centrifuged at maximum speed for 10 min to remove the protein. Next, the supernatant was taken and 1/10 volume of 3 M acetic acid (pH 5.5) as well as 3 volumes of 100% ethanol was added to precipitate the RNA at ~ 20 °C for 1.5 h. Then, the precipitated RNA was centrifuged at the maximum speed for 30 min, stored at – 4 °C and washed twice with 75% ethanol. Finally, the RNA was dissolved in RNase-free water.
The tRNA degradation reaction was done in 10 mM Tris-HCl (pH 7.4) and 100 mM NaCl using a fixed concentration of tRNA (2 µg) and different concentrations of RNase2 (up to 60 nM) or RNase5 (up to 25 µM) at room temperature during 20 min or 30 min, respectively. Following, the same volume of 2 × stop buffer (2 × TAE, 8 M urea, 0.1 M DTT and 20% glycerol) was added and samples were incubated at 95°C for 15 min before gel loading. The 12% denaturing urea polyacrylamide (NZYtech, MB15501) gel and Sybr gold (Life technologies, S11494) was used to run and stain the gel, respectively.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00182-022-04229-x.

Acknowledgements We thank Yundong Peng (Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany), Manuel Kaulich (Goethe University Frankfurt, Germany) for technical support with CRISPR design. We would also like to show our gratitude to Dr. Laura Tussel, Anna Genescà, Marina Rodriguez, and David Soler from UAB for helping in lentiviral production. We heartily thank Prof. Helene Rosenberg for helpful discussions.

Funding Open Access Funding provided by Universitat Autonoma de Barcelona. This research was founded by Research work was supported by the Ministerio de Economía y Competitividad (SAF2015-66007P), co-financed by FEDER funds, by Agencia Estatal de Investigación (PID2019-106123GB-I00/AEI/10.13039/501100011033) and by Fundació La Marató de TV3 (280310). LL and JL were supported by China Scholarship Council (CSC) predoctoral fellowships.

Data availability All data generated or analysed during this study are included in this published article (see supplementary information files).

Declarations

Conflict of interest The authors declare no conflicts of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Li J, Boix E (2021) Host defence RNases as antiviral agents against enveloped single stranded RNA viruses. Virulence 12:444–469. https://doi.org/10.1080/21505594.2021.1871823
2. Rosenberg HF (2015) Eosinophil-derived neurotoxin (EDN/RNase 2) and the mouse eosinophil-associated RNases (mEars): expanding roles in promoting host defense. Int J Mol Sci 16:15442–15455. https://doi.org/10.3390/ijms160715442
3. Acharya KR, Ackerman SJ (2014) Eosinophil granule proteins: form and function. J Biol Chem 289:17406–17415. https://doi.org/10.1074/jbc.R113.546218
4. Lee JJ, Jacobsen EA, McGarry MP et al (2010) Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy 40:563–575. https://doi.org/10.1111/j.1365-2222.2010.03484.x
5. Weller PF, Spencer LA (2017) Functions of tissue-resident eosinophils. Nat Rev Immunol 17:746–760. https://doi.org/10.1038/nri.2017.95
6. Mouziove F, Lacy P (2014) Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol 5:570. https://doi.org/10.3389/fimmu.2014.00570
7. Gleich GJ, Loegering DA, Bell MP et al (1986) Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil cationic protein: homology with ribonuclease. Proc Natl Acad Sci USA 83:3146–3150. https://doi.org/10.1073/pnas.83.10.3146
8. Rosenberg H (2008) Eosinophil-derived neurotoxin/RNase2: connecting the past, the present and the future. Curr Pharm Biotechnol 9:135–140. https://doi.org/10.2174/138920108784567236
9. Boix E, Nogués MV (2007) Mammalian antimicrobial proteins and peptides: overview on the RNase A superfamilly members involved in innate host defence. Mol Biosyst 3:317. https://doi.org/10.1039/b617527a
10. Monteseirín J, Vega A, Chacón P et al (2007) Neutrophils as a novel source of eosinophil cationic protein in IgE-mediated processes. J Immunol 179:2634–2641. https://doi.org/10.4049/jimmunol.179.4.2634
11. Lu L, Li J, Moussaoui M, Boix E (2018) Immune modulation by human secreted RNases at the extracellular space. Front Immunol 9:1–20. https://doi.org/10.3389/FIMMU.2018.01012
12. Domachowska JB, Dyer KD, Bonville CA, Rosenberg HF (1998) Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis 177:1458–1464. https://doi.org/10.1086/515322
13. Rosenberg HF, Dyer KD, Domachowska JB (2009) Respiratory viruses and eosinophils: exploring the connections. Antiviral Res 83:1–9. https://doi.org/10.1016/j.antiviral.2009.04.005
14. Malik A, Batra JK (2012) Antimicrobial activity of human eosinophil granule proteins: involvement in host defence against pathogens. Crit Rev Microbiol 38:168–181. https://doi.org/10.3109/13652222.2010.546219
15. Rodrigo-Muñoz JM, Sastre B, Cañas JA et al (2021) Eosinophil response against classical and emerging respiratory viruses: COVID-19. J Investig Allergol Clin Immunol 31:94–107. https://doi.org/10.21876/jiaci.0624
16. Rosenberg HF, Foster PS (2021) Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies. Semin Immunopathol 43:383–392. https://doi.org/10.1007/s00281-021-00850-3
17. Tan Y, Zhou J, Zhou Q et al (2021) Role of eosinophils in the diagnosis and prognostic evaluation of COVID-19. J Med Virol 93:1105–1110. https://doi.org/10.1002/jmv.26506
18. Harrison AM, Bonville CA, Rosenberg HF, Domachowska JB (1999) Respiratory syncytial virus-induced chemokine expression in the lower airways: eosinophil recruitment and degranulation. Am J Respir Crit Care Med 159:1918–1924. https://doi.org/10.1164/ajrccm.159.6.9805083
19. Rosenberg HF, Dyer KD (1997) Diversity among the primate eosinophil-derived neurotoxin genes: a specific C-terminal sequence is necessary for enhanced ribonuclease activity. Nucleic Acids Res 25:3532–3536. https://doi.org/10.1093/nar/25.17.3532
20. Borchers AT, Chang C, Gershwin ME, Gershwin LJ (2013) Respiratory syncytial virus—a comprehensive review. Clin Rev Allergy Immunol 45:331–379. https://doi.org/10.1007/s12016-013-8368-9
21. Kim C-K, Seo JK, Ban SH et al (2013) Eosinophil-derived neurotoxin levels at 3 months post-respiratory syncytial virus bronchiolitis are a predictive biomarker of recurrent wheezing. Biomarkers 18:230–235. https://doi.org/10.3109/1354750X.2013.773078

22. Rosenberg HF, Domachowske JB (1999) Eosinophils, ribonucleases and host defense: solving the puzzle. Immunol Res 20:261–274. https://doi.org/10.1007/BF02790409

23. Sikriwal D, Seth D, Parveen S et al (2012) An insertion in loop L7 of human eosinophil-derived neurotoxin is crucial for its antiviral activity. J Cell Biochem 113:3104–3112. https://doi.org/10.1002/jcb.24187

24. Lu L, Arranz-Trullén J, Prats-Ejarque G et al (2019) Human anti-microbial RNases inhibit intracellular bacterial growth and induce autophagy in mycobacteria-infected macrophages. Front Immunol. https://doi.org/10.3389/fimmu.2019.01500

25. Lu L, Wei R, Prats-Ejarque G et al (2020) Human RNase3 immune modulation by catalytic-dependent and independent modes in a macrophage-cell line infection model. Cell Mol Life Sci 1:3. https://doi.org/10.1007/s00018-020-03695-5

26. Honda S, Morichika K, Kirino Y (2016) Selective amplification and sequencing of cyclic phosphate-containing RNAs by the cP-RNA-seq method. Nat Protoc 11:476–489. https://doi.org/10.1038/nprot.2016.025

27. Anderson P, Ivanov P (2014) tRNA fragments in human health and disease. FEBS Lett 588:4297–4304. https://doi.org/10.1016/j.febslet.2014.09.001

28. Ostendorf T, Zillinger T, Andryka K et al (2020) Immune sensing of synthetic bacterial, and protozoan RNA by toll-like receptor 8 requires coordinated processing by RNase T2 and RNase 2. Immunity 52:591-605.e6. https://doi.org/10.1016/j.immuni.2020.03.009

29. Nikitina E, Larionova I, Choinzonov E, Kzhyslykowska J (2018) Monocytes and macrophages as viral targets and reservoirs. Int J Mol Sci 19:2821. https://doi.org/10.3390/ijms19092821

30. Miller AL, Bowlin TL, Lukacs NW (2004) Respiratory syncytial virus-induced chemokine production: linking viral replication to antiviral responses. J Cell Biol 165:35–42. https://doi.org/10.1083/jcb.200811106

31. Ennaciri J, Ahmad R, Menezes J (2007) Interaction of monoacyl-tRNA synthetases in retroviral replication. J Biol Chem 279:32983–32988. https://doi.org/10.1074/jbc.M700650200

32. Rosenberg HF, Domachowske JB (2012) Inflammatory responses to toxin levels at 3 months post-respiratory syncytial virus bronchiolitis. Annu Rev Microbiol 66:123–141. https://doi.org/10.1146/annurev.micro.112408.134243

33. Yang D, Chen Q, Rosenberg HF et al (2004) Human ribonuclease and sequencing of cyclic phosphate-containing RNAs by the cP-RNA-seq method. Nat Protoc 11:476–489. https://doi.org/10.1038/nprot.2004.009

34. Rugeles MT, Trubey CM, Bedoya VI et al (2003) Ribonuclease T2-based model of immunomodulatory pharmacotherapeutics. Curr Med Chem 19:1424. https://doi.org/10.2174/09298671279982346

35. Yang D, Chen Q, Rosenberg HF et al (2004) Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol 173:6134–6142. https://doi.org/10.4049/jimmunol.173.10.6134

36. Deng J, Prashkin RN, Chen Y et al (2015) Respiratory syncytial virus utilizes a tRNA fragment to suppress antiviral responses through a novel targeting mechanism. Mol Ther 23:1622–1629. https://doi.org/10.1038/mt.2015.124

37. Skalsky RL, Cullen BR (2010) Viruses, microRNAs, and host interactions. Annu Rev Microbiol 64:123–141. https://doi.org/10.1146/annurev.micro.112408.134243

38. Ghiildiyal M, Zamore PD (2009) Small silencing RNAs: an expanding universe. Nat Rev Genet 10:94–108. https://doi.org/10.1038/nrg2504

39. Wu W, Choi E-J, Lee I et al (2020) Non-coding RNAs and their role in respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) infections. Viruses 12:345. https://doi.org/10.3390/v12030345

40. Cech TR, Steitz JA (2014) The noncoding RNA revolution-trash is partly responsible for the HIV-1 inhibitory effect activated by HLA allointagen recognition. AIDS 17:481–486. https://doi.org/10.1097/00002030-200303070-00002

41. Zhovtib A, Kravets A, Gakh Y et al (2017) Identification of two novel functional tRNA-derived fragments induced in response to respiratory syncytial virus infection. J Gen Virol 98:1600–1610. https://doi.org/10.1099/vir.0.008552

42. Deng J, Prashkin RN, Chen Y et al (2015) Respiratory syncytial virus utilizes a tRNA fragment to suppress antiviral responses through a novel targeting mechanism. Mol Ther 23:1622–1629. https://doi.org/10.1038/mt.2015.124

43. Skalsky RL, Cullen BR (2010) Viruses, microRNAs, and host interactions. Annu Rev Microbiol 64:123–141. https://doi.org/10.1146/annurev.micro.112408.134243

44. Cech TR, Steitz JA (2014) The noncoding RNA revolution-trash is partly responsible for the HIV-1 inhibitory effect activated by HLA allointagen recognition. AIDS 17:481–486. https://doi.org/10.1097/00002030-200303070-00002

45. Rugeles MT, Trubey CM, Bedoya VI et al (2003) Ribonuclease T2-based model of immunomodulatory pharmacotherapeutics. Curr Med Chem 19:1424. https://doi.org/10.2174/09298671279982346

46. Deng J, Prashkin RN, Wang Q et al (2014) Human metapneumovirus infection induces significant changes in small noncoding RNA expression in airway epithelial cells. Mol Ther Nucleic Acids. https://doi.org/10.1038/mtna.2014.18

47. Bafaro K, Shigematsu M, Shababi S, Kirino Y (2020) Infection-induced 5′-half molecules of tRNAHisGUG activate toll-like receptor 7. PLoS Biol 18:e3000892. https://doi.org/10.1371/journal.pbio.3000892

48. Das AT, Klaver B, Berkhout B (1995) Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA(3Lys). J Virol 69:3090–3097. https://doi.org/10.1128/JVI.69.5.3090-3097.1995

49. Jin D, Musier-Forsyth K (2019) Role of host tRNAs and aminoacyl-tRNA synthetases in retroviral replication. J Biol Chem 294:5352–5364. https://doi.org/10.1074/jbc.REV118.002957

50. Schorn AJ, Gutbod MJ, LeBlanc C, Martiennsen R (2017) LTR-retrotransposon control by tRNA-derived small RNAs. Cell 170:61-71.e11. https://doi.org/10.1016/j.cell.2017.06.013

51. Geulich W, Wagner M, Gaitd MM et al (2019) TLRL8 is a sensor of RNase T2 degradation products. Cell 179:1264-1275.e13. https://doi.org/10.1016/j.cell.2019.11.001

52. Sorrentino S (2010) The eight human “canonical” ribonucleases: molecular diversity, catalytic properties, and special biologically actions of the enzyme proteins. FEBS Lett 584:2194–2200. https://doi.org/10.1016/j.febslet.2010.04.018

53. Boix E, Blanco IA, Nogués MV, Moussauoi M (2013) Nucleotide binding architecture for secreted cytotoxic endoribonucleases. Biochimie 95:1087–1097. https://doi.org/10.1016/j.biochi.2012.12.015

54. Su Z, Kuscu C, Malik A et al (2019) Angiogenin generates specific stress-induced tRNA halves and is not involved in tRF-3-mediated
56. Suhasini AN, Sirdeshmukh R (2006) Transfer RNA cleavages by onconase reveal unusual cleavage sites. J Biol Chem 281:12201–12209. https://doi.org/10.1074/jbc.RA119.009272

57. Ardelt W, Ardelt B, Darzynkiewicz Z (2009) Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmocol 625:181–189. https://doi.org/10.1016/j.ejphar.2009.06.067

58. Akiyama Y, Tomioka Y, Abe T et al (2021) In lysate RNA digestion provides insights into the angiogenin’s specificity towards transfer RNAs. RNA Biol. https://doi.org/10.1080/15476286.2021.1930758

59. Prats-Ejarque G, Lu L, Salazar VA et al (2019) Evolutionary trends in RNA base selectivity within the RNase A superfamily. Front Pharmacol 10:1170. https://doi.org/10.3389/fphar.2019.01170

60. Leonidas DD, Shapiro R, Irons LI et al (1999) Toward rational design of ribonuclease inhibitors: high-resolution crystal structure of a ribonuclease A complex with a potent 3',5'-pyrophosphate-linked dinucleotide inhibitor. Biochemistry 38:10287–10297. https://doi.org/10.1021/bi990900W

61. Holloway DE, Chavali GB, Leonidas DD et al (2009) Influence of naturally-occurring S'-pyrophosphate-linked substituents on the binding of adenylic inhibitors to ribonuclease a: an X-ray crystallographic study. Biopolymers 91:995–1008. https://doi.org/10.1002/bip.21158

62. Shepard SM, Windsor IW, Raines RT, Cummins CC (2019) Nucleoside tetra- and pentaphosphates prepared using a tetraphosphorylation reagent are potent inhibitors of ribonuclease A. J Am Chem Soc 141:18400–18404. https://doi.org/10.1021/jacs.9b09760

63. Lee JE, Bae E, Bingman CA et al (2008) Structural basis for catalysis by onconase. J Mol Biol 375:165–177. https://doi.org/10.1016/j.jmb.2007.09.089

64. Yu X, Xie Y, Zhang S et al (2021) tRNA-derived fragments: mechanisms underlying their regulation of gene expression and potential applications as therapeutic targets in cancers and virus infections. Theranostics 11:237–247. https://doi.org/10.4161/rna.7.7.2420

65. Saxena SK, Sirdeshmukh R, Ardelt W et al (2002) Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family. J Biol Chem 277:15142–15146. https://doi.org/10.1074/jbc.M101815200

66. Sarangdhar MA, Allam R (2021) Angiogenin (ANG)—ribonuclease inhibitor (RNHI) system in protein synthesis and disease. Sci Adv 7:eaaz4220.

67. Ivanov P, Emara MM, Villen J et al (2011) Angiogenin-induced tRNA fragments inhibit translation initiation. Mol Cell 43:613–623. https://doi.org/10.1016/j.molcel.2011.06.022

68. Choi E-J, Ren J, Zhang K et al (2020) The importance of AGO 1 and 4 in post-transcriptional gene regulatory function of tU5'-GluCTC, an respiratory syncytial virus-induced tRNA-derived RNA fragment. Int J Mol Sci 21:8766. https://doi.org/10.3390/ijms21228766

69. Kellner S, Burhene J, Helm M (2010) Detection of RNA modifications. RNA Biol 7:237–247. https://doi.org/10.4161/rna.7.2.11468

70. Pizzo E, Sarcinelli C, Sheng J et al (2013) Ribonuclease/angiogenin inhibitor 1 regulates stress-induced subcellular localization of angiogenin to control growth and survival. J Cell Sci 126:4308–4319. https://doi.org/10.1242/jcs.134551

71. Rashad S, Tominaga T, Niizuma K (2021) The cell and stress-specific canonical and noncanonical tRNA cleavage. J Cell Physiol 236:3710–3724. https://doi.org/10.1002/jcp.30107

72. Shigematsu M, Kirino Y (2020) Oxidative stress enhances the expression of 2',3'-cyclic phosphate-containing RNAs. RNA Biol 17:1060–1069. https://doi.org/10.1080/15476286.2020.1766861

73. Li S, Hu G-F (2012) Emerging role of angiogenin in stress response and cell survival under adverse conditions. J Cell Physiol 227:2822–2826. https://doi.org/10.1002/jcp.23051

74. Xin X, Wang H, Han L et al (2018) Single-cell analysis of the impact of host cell heterogeneity on infection with foot-and-mouth disease virus. J Virol 92:e00179-e218. https://doi.org/10.1128/JVI.00179-18

75. Zhang X, Cozen AE, Liu Y et al (2016) Small RNA modifications: integral to function and disease. Trends Mol Med 22:1025–1034. https://doi.org/10.1016/j.molmed.2016.10.009

76. Akiyama Y, Kharel P, Abe T et al (2020) Isolation and initial structure-functional characterization of endogenous tRNA-derived stress-induced RNAs. RNA Biol. https://doi.org/10.1080/15476286.2020.1732702

77. Jain S, Wheeler JR, Walters RW et al (2016) ATPase-modulated stress granules contain a diverse proteome and substructure. Cell 164:487–498. https://doi.org/10.1016/J.CELL.2015.12.038

78. Shigematsu M, Kawamura T, Kirino Y (2018) Generation of 2',3'-cyclic phosphate-containing RNAs as a hidden layer of the transcriptome. Front Genet 9:562. https://doi.org/10.3389/fgen.2018.00562

79. Shigematsu M, Morichika K, Kawamura T et al (2019) Genome-wide identification of short 2',3'-cyclic phosphate-containing RNAs and their regulation in aging. PLoS Gen 15:e1008469. https://doi.org/10.1371/journal.pgen.1008469

80. Schimmelp P (2018) The emerging complexity of the tRNA world: mammalian tRNAs beyond protein synthesis. Nat Rev Mol Cell Biol 19:45–58. https://doi.org/10.1038/nrm.2017.77

81. Al Yacoub N, Romanowska M, Haritonova N, Foerster J (2007) Acceleration of export from the nucleus to the cytoplasm and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2:495–505. https://doi.org/10.1038/nprot.2009.22

82. Tiscornia G, Singer O, Verma IM (2006) Production and purification of lentiviral vectors containing large inserts. J Gene Med. https://doi.org/10.1002/jgm.1052

83. Kutner RH, Zhang X-Y, Reiser J (2009) Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 4:495–505. https://doi.org/10.1038/nprot.2009.22

84. Tiscornia G, Arranz-Trullén J, Blanco JA et al (2016) Production and purification of lentiviral vectors. Nat Protoc 1:241–245. https://doi.org/10.1038/nprot.2006.37

85. Shen B, Zhang J, Wu H et al (2013) Generation of genome-modified mice via Cas9/RNA-mediated gene targeting. Cell Res 23:720–723. https://doi.org/10.1038/cr.2013.46

86. Prats-Ejarque G, Arranz-Trullén J, Blanco JA et al (2016) The first crystal structure of human RNase 6 reveals a novel substrate-binding and cleavage site arrangement. Biochem J 473:1523–1536. https://doi.org/10.1042/BCJ20160245

87. Vissers M, Habets MN, Ahout IML et al (2013) An in vitro model to study immune responses of human peripheral blood mononuclear cells to human respiratory syncytial virus infection. J Vis Exp. https://doi.org/10.3791/50766

88. Sun Y, Jain D, Koziol-White CJ et al (2015) Immunostimulatory defective viral genomes from respiratory syncytial virus promote a strong innate antiviral response during infection in mice and humans. PLOS Pathog 11:e1005122. https://doi.org/10.1371/journal.ppat.1005122

89. Dewhurst-Maridor G, Simonet V, Bornand J et al (2004) Development of a quantitative TaqMan RT-PCR for respiratory syncytial virus. J Virol Methods 120:41–49. https://doi.org/10.1016/J.JVIROMET.2004.03.017
90. Jiang H, Lei R, Ding S-W, Zhu S (2014) Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinformatics 15:182. https://doi.org/10.1186/1471-2105-15-182
91. Langmead B, Trapnell C, Pop M, Salzberg SL (2009) Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 10:R25. https://doi.org/10.1186/gb-2009-10-3-r25
92. Axtell MJ (2013) ShortStack: comprehensive annotation and quantification of small RNA genes. RNA 19:740–751. https://doi.org/10.1261/rna.035279.112
93. Anders S, Pyl PT, Huber W (2015) HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31:166–169. https://doi.org/10.1093/BIOINFORMATICS/BTU638
94. Griffiths-Jones S (2006) miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 34:D140–D144. https://doi.org/10.1093/nar/gkj112
95. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https://doi.org/10.1186/s13059-014-0550-8
96. Lukavsky PJ, Puglisi JD (2004) Large-scale preparation and purification of polyacrylamide-free RNA oligonucleotides. RNA 10:889–893. https://doi.org/10.1261/rna.5264804
97. Sikriwal D, Seth D, Dey P, Batra JK (2007) Human eosinophil-derived neurotoxin: involvement of a putative non-catalytic phosphate-binding subsite in its catalysis. Mol Cell Biochem 303:175–181. https://doi.org/10.1007/s11010-007-9471-0
98. Sorrentino S (1998) Human extracellular ribonucleases: multiplicity, molecular diversity and catalytic properties of the major RNase types. Cell Mol Life Sci 54:785–794. https://doi.org/10.1007/s000180050207

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Lu Lu1,2 · Jiarui Li1 · Ranlei Wei3 · Irene Guidi1 · Luca Cozzuto4 · Julia Ponomarenko4 · Guillem Prats-Ejarque1 · Ester Boix1

1 Department of Biochemistry and Molecular Biology, Faculty of Biosciences, Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain
2 College of Animal Science and Technology, Sichuan Agricultural University, Chengdu, Sichuan, China
3 National Frontier Center of Disease Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China
4 Bioinformatic Unit, Centre de Regulació Genòmica (CRG), Barcelona, Spain